A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Phase 1

Completed

• Conditions: Psoriasis
• Interventions: Drug: LY3316531 - IV; Drug: Placebo - IV; Drug: LY3316531 - SC

• Registration Number: NCT03418493
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).

This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-01-26
• Study First Submitted QC: 2018-01-26
• Study Start: 2018-01-30
• Study First Posted: 2018-02-01
• Primary Completion: 2018-12-24
• Study Completion: 2019-07-29
• Status Verified: 2022-11-01
• Results First Submitted: 2022-11-11
• Results First Submitted QC: 2022-11-11
• Last Update Submitted: 2022-11-11
• Results First Posted: 2023-09-21
• Last Update Posted: 2023-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

• Healthy Participants

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Females must be of non-childbearing potential
  • Are between 18 and 64 years of age, inclusive, at screening
  • Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²) inclusive
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

• Psoriasis Participants:

  • Chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline
  • Meet psoriasis disease activity criteria
  • Are at least 18 years of age
  • Have a minimum body weight of 50 kilograms (kg)

Read More

Exclusion Criteria

• Healthy and Psoriasis Participants

  • Have known or ongoing neuropsychiatric disorders
  • Have received live vaccine(s) (included attenuated live vaccines) within 28 days of screening or intend to during the study
  • Have had any malignancy within the past 5 years except for basal cell or squamous cell epithelial carcinomas of the skin that have been resected with no subsequent evidence of recurrence for at least 3 years prior to screening and cervical carcinoma in situ with no evidence of recurrence within 5 years prior to baseline
  • Show evidence of active or latent tuberculosis (TB)
  • Have presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic or neuropsychiatric disorders or abnormal laboratory values at screening that, in the opinion of the investigator, pose an unacceptable risk to the participant if participating in the study or of interfering with the interpretation of data

• Psoriasis Participants Only:

  • Have received treatment with biologic therapies for psoriasis (such as monoclonal antibodies, including marketed or investigational biologic therapy)
  • Prior or current use of biologics for indications other than psoriasis may be allowed with sponsor approval
  • Have received systemic nonbiologic psoriasis therapy within 28 days of baseline
  • Have received topical psoriasis treatment within 14 days of baseline

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LY3316531 (Part A)	LY3316531 - IV	Participants received single doses of 3 milligrams (mg), 15 mg, 75 mg, 300 mg, 900 mg, or 2000 mg LY3316531 administered Intravenously (IV), or 300 mg LY3316531 administered Subcutaneously (SC).
LY3316531 (Part A)	LY3316531 - SC	Participants received single doses of 3 milligrams (mg), 15 mg, 75 mg, 300 mg, 900 mg, or 2000 mg LY3316531 administered Intravenously (IV), or 300 mg LY3316531 administered Subcutaneously (SC).
Placebo (Part A)	Placebo - IV	Placebo matching LY3316531 administered IV.
LY3316531 (Part B)	LY3316531 - IV	Participants received 3 doses of 2000 mg LY3316531 administered IV (1 dose every 4 weeks).
Placebo (Part B)	Placebo - IV	Placebo matching LY3316531 administered IV.
LY3316531 (Part C)	LY3316531 - IV	Participants with psoriasis received single doses of 300 mg LY3316531 administered IV.

Primary Outcome Measures

Name	Time	Method
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Pre-dose up to 1 year after administration of study drug	A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is reported in the Reported Adverse Events module.; An SAE is any adverse event from this study that results in 1 of the following: 1. Death; 2. Initial or prolonged inpatient hospitalization; 3. A life-threatening experience (that is, immediate risk of dying); 4. Persistent or significant disability/incapacity; 5. Congenital anomaly/birth defect; 6. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above.

Secondary Outcome Measures

Name	Time	Method
Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531	Pre-dose, Days 1 (End of infusion [IV], 2 hrs after start of infusion [IV], 6 hrs after start of infusion [IV] or injection [SC]), 2 (24 hrs after start of infusion [IV] or injection [SC]), 4, 8, 11 (SC only), 15, 22, 29, 43, 57, 71, 85 post- dose	PK: Cmax of LY3316531. Under time frame, hours was abbreviated as "hrs."
Part B: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531	Days 57 (Pre-dose, end of infusion), 58, 60, 64, 67, 71, 78, and 85	PK: Cmax of LY3316531 following the Day 57 dose.
Part C: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531	Pre-dose, Days 1 (End of infusion, 2 hrs after start of infusion, 6 hrs after start of infusion), 2 (24 hrs after start of infusion), 4, 8, 15, 22, 29, 43, 57, 71, 85, and 113 post-dose	PK: Cmax of LY3316531.
Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞)	Pre-dose, Days 1 (End of infusion [IV], 2 hrs after start of infusion [IV], 6 hrs after start of infusion [IV] or injection [SC]), 2 (24 hrs after start of infusion [IV] or injection [SC]), 4, 8, 11 (SC only), 15, 22, 29, 43, 57, 71, 85 post- dose	Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞).
Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 Over the Dosing Interval (Tau) - AUCtau	Days 57 (Pre-dose, end of infusion), 58, 60, 64, 67, 71, 78, and 85	AUC of LY3316531 over the dosing interval (tau = 672 h = 28 days) following the Day 57 dose.
Part C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞)	Pre-dose, Days 1 (End of infusion, 2 hrs after start of infusion, 6 hrs after start of infusion), 2 (24 hrs after start of infusion), 4, 8, 15, 22, 29, 43, 57, 71, 85, and 113 post-dose	Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞).

Trial Locations

Locations (2)

PAREXEL-Phase 1 Baltimore Harbor Hospital Center; 🇺🇸 Baltimore, Maryland, United States

Parexel Early Phase Unit at Glendale; 🇺🇸 Glendale, California, United States